What is Science & Humans?
Science & Humans operates as a sophisticated online hormone therapy and wellness clinic, offering a comprehensive suite of integrative health services. The platform addresses a wide spectrum of physiological needs, including perimenopause, menopause, reproductive hormone health, weight optimization, and specialized treatments for hair regrowth and erectile dysfunction. By utilizing a clinician-guided model, the company ensures that patients receive personalized care plans that are both evidence-based and convenient.
Beyond direct-to-consumer services, Science & Humans has carved out a strategic niche by partnering with employers and insurers. This B2B2C approach is designed to enhance workforce health and productivity, positioning the company as a vital player in the evolving digital health ecosystem. Their commitment to data-driven, patient-centric outcomes distinguishes them in a competitive market, providing a scalable solution for complex health management.
How much funding has Science & Humans raised?
Science & Humans has raised a total of $7.2M across 1 funding round:
Series A
$7.2M
Series A (2026): $7.2M with participation from Canadian Imperial Bank of Commerce, WELL Health Technologies Corp, and Pender Ventures
Key Investors in Science & Humans
Canadian Imperial Bank of Commerce
CIBC Innovation Banking provides specialized financial solutions, including credit and lending, tailored to support the growth of high-potential technology and health-tech companies.
WELL Health Technologies Corp
A practitioner-focused digital health leader that operates an extensive network of primary and specialty care clinics, alongside a robust suite of telehealth and electronic medical record platforms.
Pender Ventures
A venture capital firm specializing in B2B software and health tech, providing strategic support to startups during the critical transition from commercialization to scaling.
What's next for Science & Humans?
With the successful closure of this Series A round, Science & Humans is poised to enter a period of aggressive growth and operational refinement. The strategic roadmap likely includes the expansion of its clinical network, the enhancement of its digital patient engagement platforms, and the deepening of its partnerships with major Canadian insurers. By focusing on the intersection of hormone health and workforce productivity, the company is set to capture a larger share of the preventative health market.
The involvement of institutional investors suggests a high degree of confidence in the company's ability to navigate the regulatory complexities of the Canadian healthcare sector while maintaining a high standard of care. Future initiatives will likely prioritize the integration of advanced diagnostic tools and the scaling of their proprietary care delivery model to meet the increasing demand for specialized, remote-first medical services.
